BioCentury
ARTICLE | Clinical News

14-type high-risk HPV test: Interim post-marketing study data

April 5, 2010 7:00 AM UTC

Interim data from 5,043 patients in the Chinese post-marketing SHENCCAST II trial in >10,000 women showed that Hologic's Cervista HPV HR test had 90.7% sensitivity and 90.2% specificity for histologic...